Joint Clinical Assessment, JCA
Tovorafenib (Glioma)
Dossier assessment
Indication:
Treatment of paediatric low-grade glioma (LGG)
Press releases
A significant step in the new EU HTA process: first assessment completed
The new European benefit assessment has reached an important milestone: the first joint assessment, in which IQWiG was directly involved as the co-assessor, has been approved by the Member State Coordination Group on HTA.
First EU HTAs with IQWiG involvement launched
The Institute is involved in four oncology drug assessments as an assessor or co-assessor.
Timetable
- 1st quarter, 2025
- Start
- 2nd quarter, 2026
- voraussichtlicher Abschluss
Project details
- Project no.
- MP-202406
- Report type
- Joint Clinical Assessment, JCA
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the NCPE (National Centre for Pharmacoeconomics) Ireland.
The joint clinical assessment will be published on the European Commission’s website: health.ec.europa.eu/publications/joint-clinical-assessment-report-tovorafenib-ojemda_en
Further background information can be found here: European health technology assessment